Ser175

Site Information
RPVsAsRssLDLsyy SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 457527

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 ) , mutation of modification site ( 4 )
Disease tissue studied:	breast cancer ( 2 ) , breast ductal carcinoma ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 , 2 )
Relevant cell line - cell type - tissue:	breast ( 1 , 2 ) , Jurkat (T lymphocyte) ( 3 )

Downstream Regulation
Effects of modification on emerin:	molecular association, regulation ( 4 )
Inhibit interaction with:	BAF (human) ( 4 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
3	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
4	Hirano Y, et al. (2005) Dissociation of emerin from barrier-to-autointegration factor is regulated through mitotic phosphorylation of emerin in a xenopus egg cell-free system. J Biol Chem 280, 39925-33 16204256 Curated Info